comparemela.com
Home
Live Updates
Amivantamab Provides Long-term Clinical Benefit in Post-Platinum EGFR Exon 20 Insertion+ NSCLC : comparemela.com
Amivantamab Provides Long-term Clinical Benefit in Post-Platinum EGFR Exon 20 Insertion+ NSCLC
Amivantamab continued to be tolerable and efficacious in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.
Related Keywords
Madrid
,
Spain
,
Copenhagen
,
Køavn
,
Denmark
,
Pilar Garrido
,
Daiichi Sankyo
,
University Hospital Ram
,
Pfizer
,
Boehringer Ingelheim
,
Novartis
,
Oncology Department
,
Amgen
,
Glaxosmithkline
,
Bristol Myers Squibb
,
European Lung Cancer Congress
,
Astrazeneca
,
Lung Cancer
,
Universidad De Alcal
,
Thoracic Tumours Section
,
Medical Oncology Department
,
Lung Cancer Congress
,
Epidermal Growth Factor Receptor
,
Amivantamab
,
Egfr Exon 20 Insertion Mutation
,
Non Small Cell Lung Cancer
,
Nsclc
,
Felcc
,
Chrysalis
,
Nct02609776
,
comparemela.com © 2020. All Rights Reserved.